ORAL Silymarin FOR CHRONIC HEPATITIS C - A RETROSPECTIVE ANALYSIS COMPARING THREE DOSE REGIMENS

R. Huber1, I. Futter1, R. Lüdtke2
1Center for Complementary Medicine, Department of Internal Medicine II, University Hospital Freiburg, Germany
2Karl and Veronica Carstens-Foundation, Essen, Germany

Abstract: To investigate the effects of silymarin on aminotransferase levels in patients with chronic hepatitis C, a standardized dose of 420 mg, 840 mg or 1260 mg per day was performed in patients of our clinic, who were not eligible for treatment with pegylated interferon and ribavirin. Aminotransferase levels were determined before, at 3-6 week intervals during and at the end of treatment. Predefined inclusion criteria for the retrospective analysis were persistently elevated alanine aminotransferase (ALT) levels (at least 6 months prior to and at beginning of the treatment) and treatment duration of at least three weeks. Liver cirrhosis CHILD B or C, interferon therapy within the last three months before treatment with silymarin, alcohol use >30 g/d, coinfection with hepatitis B virus or other severe diseases were exclusion criteria. According to these criteria 40 patients (13 with 420 mg, 20 with 840 mg and 7 with 1260 mg silymarin per day) were eligible for the analysis. The mean treatment period was 125 ± 78 days. ALT, aspartate aminotransferase and γ glutamyltransferase levels did not change significantly from baseline in any group and there were no differences between the treatment groups. Bilirubin and prothrombine time were normal in all but one patient and remained unchanged. Silymarin therapy had no side effects. Silymarin at the doses used, does not improve elevated aminotransferases in patients with chronic hepatitis C.

Key words: milk thistle, silybin, aminotransferase levels

INTRODUCTION

Standard therapy for the chronic hepatitis C with pegylated interferon and ribavirin results in sustained response rates of about 50% in patients infected with genotype 1. Therefore, therapeutic alternatives are of major importance. Silymarin is one of the most frequently used ‘liver support drugs’ in Germany and has a good bioavailability (Schulz et al. 1995). There were 3 prospectively planned treatment groups; group 1 received 3 x 420 mg/day as recommended by the manufacturer, group 2 received 3 x 280 mg/day and group 3 3 x 420 mg/day. The allocation to the different groups by the physician was arbitrary. There was no sociodemographic or disease related criterion for the allocation. If, however, a patient had received any of the 3 treatments in the past, he did not receive the same treatment again. Follow up visits in intervals of 3-6 weeks were prospectively planned. At each visit aminotransferase levels, side effects and the compliance were documented. The treatment was stopped after 3 months, if no reduction of the ALT level or a subjective benefit had occurred.

Predefined inclusion criteria for the retrospective analysis were age between 25 and 85 years, persistent elevated ALT levels (>23 U/l) at least 6 months prior to and at beginning of the treatment and treatment duration of at least three weeks. Liver cirrhosis...
CHILD B or C, interferon therapy within the last three months before treatment with silymarin, alcohol use >30 g/d, coinfection with hepatitis B virus, pregnancy, severe concomitant diseases (HIV, malignancies, autoimmune diseases etc.) or participation in a clinical trial were exclusion criteria. The main outcome parameter was the ALT level. Secondary parameters were AST, GGT, bilirubin and prothrombine time as well as side effects.

**Statistical Analysis**

All analyses were done on an intention-to-treat basis. This means that all patients who once had been included were analyzed regardless whether other medications were used or whether they complied with the treatment or not.

ALT, AST and GGT levels were modelled on the basis of generalized linear models (Diggle et al. 1994). Here, we assumed the treatment course to be linear in time and the serial correlation to be exponential in time. The respective baseline values were incorporated into the models as fixed factors. Group comparisons were based on appropriate F-Tests within these models. The results are presented as estimated values after 90 days of follow-up for a hypothetical patient who started with a baseline value of 50.

**Results**

Among 195 patients with chronic hepatitis C who attended our outpatient clinic between 1998 and 2003, 40 fulfilled the in- and exclusion criteria and were included into the analysis. The patient characteristics are shown in Table 1 and 2. 21/40 patients (group 1: 4/13, group 2: 13/20, group 3: 4/7) were interferon naive either because they had refused or because of contraindications. The mean duration of the HCV infection was 15 ± 9 years (group 1: 17 ± 8, group 2: 13 ± 9, group 3: 15 ± 7). All patients were infected with genotype 1, 25% had liver cirrhosis Child A.

The mean duration of therapy was 125 ± 78 days (Table 1) and the mean number of visits during the therapy in the three groups was 3.4, 3.4 and 3.6 respectively. The aminotransferase levels at the end of treatment and calculated for a baseline level of 50 U/l after 90 days treatment are shown in Table 2. There were no significant changes of the ALT, AST or GGT levels compared to the baseline and no significant differences between the groups (Table 2).

**Table 1.** Basic characteristics as absolute numbers or means ± standard deviation.

<table>
<thead>
<tr>
<th>Silymarin 420 mg</th>
<th>Number of patients</th>
<th>Duration of treatment (days)</th>
<th>Patients age (years)</th>
<th>male/ female</th>
</tr>
</thead>
<tbody>
<tr>
<td>13</td>
<td>118 ± 86</td>
<td>59 ± 7</td>
<td>11/2</td>
<td></td>
</tr>
<tr>
<td>Silymarin 840 mg</td>
<td>20</td>
<td>134 ± 78</td>
<td>53 ± 13</td>
<td>12/8</td>
</tr>
<tr>
<td>Silymarin 1260 mg</td>
<td>7</td>
<td>111 ± 67</td>
<td>50 ± 16</td>
<td>4/3</td>
</tr>
<tr>
<td>Total</td>
<td>40</td>
<td>125 ± 78</td>
<td>55 ± 13</td>
<td>27/13</td>
</tr>
</tbody>
</table>

**Table 2.** Aminotransferase and γ-glutamyltransferase levels during treatment with Silymarin. Means ± standard deviations and estimated means and 95% confidence intervals for a treatment period of 90 days and a hypothesized baseline level of 50 U/l.

<table>
<thead>
<tr>
<th>Daily doses</th>
<th>Baseline</th>
<th>End of treatment</th>
<th>Estimated mean</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALT</td>
<td>420 mg*</td>
<td>91 ± 42</td>
<td>85 ± 51</td>
</tr>
<tr>
<td></td>
<td>840 mg**</td>
<td>65 ± 32</td>
<td>58 ± 32</td>
</tr>
<tr>
<td></td>
<td>1260 mg***</td>
<td>64 ± 26</td>
<td>61 ± 25</td>
</tr>
<tr>
<td>Total****</td>
<td>73 ± 36</td>
<td>67 ± 39</td>
<td>49 (30 to 69)</td>
</tr>
</tbody>
</table>

| AST         | 420 mg*  | 56 ± 23          | 53 ± 32        | 54 (39 to 68) |
|             | 840 mg** | 39 ± 23          | 36 ± 19        | 54 (39 to 70) |
|             | 1260 mg***| 34 ± 14          | 32 ± 15        | 52 (33 to 70) |
| Total****   | 44 ± 23  | 40 ± 24          | 54 (41 to 67)  |

| GGT         | 420 mg*  | 73 ± 59          | 69 ± 61        | 58 (39 to 78) |
|             | 840 mg** | 55 ± 70          | 46 ± 50        | 44 (27 to 61) |
|             | 1260 mg***| 47 ± 30          | 41 ± 36        | 49 (27 to 72) |
| Total****   | 59 ± 60  | 53 ± 52          | 49 (34 to 64)  |

* n = 13, ** n = 20, ***n = 7, ****n = 40
No adverse events were reported in any of the 3 groups. Bilirubin and prothrombine time were normal in all but one patient (1.6 mg/dl). The bilirubin level of all patients was 0.7 ± 0.3 mg/dl and prothrombine time was 94 ± 7 %. There were no significant changes during therapy.

**DISCUSSION**

Patients with chronic hepatitis C who were not eligible for the standard treatment were treated with 480, 840 or 1260mg silymarin per day to investigate, whether this treatment improves elevated aminotransferase levels. The follow up schedule was prospectively planned. The retrospective analysis demonstrates that aminotransferase levels didn’t change during treatment with silymarin. Although this study had no control group, it can be concluded, that silymarin in the doses tested, can not be recommended to lower elevated aminotransferase levels in these patients.

The ALT is generally used in HCV infected patients to demonstrate a therapeutic response. It reflects to a certain extent the inflammatory activity in the liver (Lee et al. 2001, Pradat et al. 2002, Shiffman et al. 2000). We therefore used the ALT as the main outcome parameter.

Silymarin was investigated up to a dose of 1260 mg/d that is three times higher than the recommended daily dose. Therefore, the lack of efficacy of silymarin cannot be due to under dosing. Further, in patients treated for more than 90 days, because they subjectively felt a benefit, ALT levels did not change (data not shown).

The patients came to our clinic with the specific request for an alternative treatment and therefore were highly motivated. Furthermore, the patients’ compliance was documented at each visit. Therefore, noncompliance can be excluded as a cause for lack of efficacy. The standardized follow up schedule in intervals of 3-6 weeks, the determination of aminotransferase levels in the quality controlled central laboratory of the University Hospital Freiburg and the restriction to HCV infected patients with permanently elevated aminotransferase levels support the internal and external validity of our results. In our study we cannot assess the treatment effects on subjective benefits, because we did not document these data systematically. Furthermore, we cannot comment on antifibrotic or antiviral effects of the medications.

**Acknowledgment:** We thank Prof. Hubert E. Blum for his help and critical comments. Our work was financially supported by the Karl and Veronica Carstens-Foundation.

**REFERENCES**


**Address for correspondence:**
Dr. Roman Huber
University Hospital Freiburg
Department of Internal Medicine II
Hugstetter Strasse 55
D-79106 Freiburg, Germany
Phone: ++49-761-270-7301
Fax: ++49-761-270-5440
E-mail: rhuber@med1.ukl.uni-freiburg.de

**Received:** August 23, 2004 / **Accepted:** January 27, 2005